On May 19, 2021 xCures reported their collaboration with the FibroFighters Foundation to launch a real-time learning platform for the Fibrolamellar Hepatocellular Carcinoma (FLHCC) community (Press release, xCures, MAY 19, 2021, View Source [SID1234584919]). FLHCC is a rare cancer primarily affecting adolescents and young adults. With an annual incidence of fewer than 300 cases, little is known regarding the best treatment options.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The xCures platform is a direct-to-patient research program that brings together patients, clinicians, patient advocates, and researchers, to accelerate the understanding of cancers and find better treatments faster.
Tom Stockwell, Executive Director of FibroFighters commented "We are very excited to be working with xCures on this important project". "This platform will have an immediate impact across many of our patients’ lives." He added, "I only wish this extremely valuable tool could have been available during my son’s fight." Tom has dedicated his life to helping FLHCC patients and families.
"xCures, FibroFighters, and the entire Fibrolamellar patient community are working together to advance knowledge about FLHCC across the country and around the world," stated Mika Newton, xCures’ CEO. "This partnership will leverage access to leading therapeutics, diagnostics, and algorithms to improve patient outcomes at the point of care and provide much needed real-time data for doctors treating this rare cancer."
For FLHCC patients, xCures integrates medical records into a clear patient summary report suitable for sharing with their oncologist, including their case summary, a list of top options, the rationale supporting each recommendation, and how to access the options.
Treatment options are informed by real-world data collected on the xCures platform, learning from the experiences of all FLHCC patients, and using AI algorithms to better understand which treatments work better for different FLHCC patients and why. Novel options and therapeutic rationales are sourced from expert oncologists and key opinion leaders in treatment of FLHCC.
xCures also helps patients access treatment options through trial matching, managed access, compassionate use programs, and by supporting insurance coverage of treatments with data. At the patient’s request, xCures may also convene a Virtual Tumor Board (VTB) where nationally recognized cancer experts further refine the xCures options summary based on a discussion of the patient’s personal medical history and preferences.
xCures and FibroFighters are actively assembling this expert panel for the Fibrolamellar community.